Cargando…
985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial
BACKGROUND: In DISCOVER, emtricitabine/tenofovir alafenamide (F/TAF) was noninferior to F/tenofovir disoproxil fumarate (TDF) for preexposure prophylaxis (PrEP) in men who have sex with men and transgender women, with a superior renal laboratory profile. The differential impact of F/TAF and F/TDF on...
Autores principales: | Daar, Eric, Brunetta, Jason, Cua, Eric, Flamm, Jason, Asmuth, David, Carter, Christoph C, Shao, Yongwu, Wong, Pamela, Ebrahimi, Ramin, Das, Moupali, Brainard, Diana M, Clarke, Amanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776228/ http://dx.doi.org/10.1093/ofid/ofaa439.1171 |
Ejemplares similares
-
995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020) -
999. Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence: Results from the DISCOVER trial
por: Glidden, David V, et al.
Publicado: (2020) -
1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019) -
Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial
por: Glidden, David V, et al.
Publicado: (2021) -
1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)